Tamar Murray

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

David Ishola, Daniela Manno, Muhammed O. Afolabi et al. · The Lancet Infectious Diseases · 2021 · 95 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +13

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

Muhammed O. Afolabi, David Ishola, Daniela Manno et al. · The Lancet Infectious Diseases · 2021 · 93 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial

Melinda Hamer, Katherine V. Houser, Amelia R. Hofstetter et al. · The Lancet · 2023 · 65 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates

Ruth Hunegnaw, Anna N. Honko, Lingshu Wang et al. · Science Translational Medicine · 2022 · 42 citations

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial

Betty Mwesigwa, Katherine V. Houser, Amelia R. Hofstetter et al. · The Lancet Infectious Diseases · 2023 · 24 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +15